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Self-assembly of 5,10,15,20-tetra(4-pyridyl)porphyrin (tpp-H2) and 5,10,15,20-tetra(4-pyridyl)porphyrin-M(II) (M¼Ni
(tpp-Ni); Zn (tpp-Zn)) tetradentate panels with the dinuclear p-cymene ruthenium clips [Ru2(p-cymene)2(C2O4)Cl2] and
[Ru2(p-cymene)2(C6H2O4)Cl2] (C2O4¼ oxalato; C6H2O4¼ 2,5-dioxydo-1,4-benzoquinonato) affords the cationic
organometallic cubes: [Ru8(p-cymene)8(tpp-H2)2(C2O4)4]
8þ (1); [Ru8(p-cymene)8(tpp-Ni)2(C2O4)4]
8þ (2); [Ru8(p-
cymene)8(tpp-Zn)2(C2O4)4]
8þ (3); [Ru8(p-cymene)8(tpp-H2)2(C6H2O4)4]
8þ (4); [Ru8(p-cymene)8(tpp-Ni)2(C6H2O4)4]
8þ (5);
and [Ru8(p-cymene)8(tpp-Zn)2(C6H2O4)4]
8þ (6). In addition, the new dinuclear arene ruthenium 2,5-dioxydo-1,4-
benzoquinonato clips [Ru2(indane)2(C6H2O4)Cl2] (7) and [Ru2(nonylbenzene)2(C6H2O4)Cl2] (8) react in methanol
with tpp-H2 in the presence of silver triflate to afford the corresponding cationic cubes [Ru8(indane)8(tpp-
H2)2(C6H2O4)4]
8þ (9) and [Ru8(nonylbenzene)8(tpp-H2)2(C6H2O4)4]
8þ (10) respectively. All cationic metalla-cubes
were isolated as triflate salts and characterized by NMR, infrared, electro-spray mass spectrometry and UV-visible
spectroscopy. Moreover, the formation of unsymmetrical metalla-cubes built using a mixture of the different porphyrin
panels during the self-assembly of the 2,5-dioxydo-1,4-benzoquinonatometalla-cubes, [Ru8(p-cymene)8(tpp-H2)(tpp-Ni)
(C6H2O4)4]
8þ (11), [Ru8(p-cymene)8(tpp-H2)(tpp-Zn)(C6H2O4)4]
8þ (12), and [Ru8(p-cymene)8(tpp-Ni)(tpp-Zn)
(C6H2O4)4]
8þ (13), was studied by electro-spray mass spectrometry. The cytotoxicities of all metalla-cubes as well as
the mixtures containing the unsymmetrical metalla-cubes were established on human ovarian A2780 and A2780cisR
cancer cell lines. All symmetrical compounds are equally cytotoxic (IC50¼7–15 mM) (IC50 being the drug concentration
necessary for 50% inhibition of cell viability) against both A2780 and cisplatin-resistant A2780cisR cancer cells, with
stronger cytotoxicities (IC50¼ 2–5mM) observed for the mixtures containing the unsymmetrical 2,5-dioxydo-1,4-
benzoquinonato metalla-cubes.
Introduction
Most solid tumours possess a unique extracellular environment
comprising a hypervasculature, a defective vascular archi-
tecture, and impaired lymphatic drainage.[1] The resulting
enhanced vascular permeability of solid tumours has became
an effective way to target cancer cells.[2] Whereas the normal
endothelial layer surrounding the blood vessels feeding healthy
cells restricts the size of molecules that can diffuse from the
blood, the endothelial layer of blood vessels in diseased tissues
is more porous towards large molecules, providing access to the
surrounding cancer cells. Moreover, diseased tissue does not
usually have a lymphatic drainage system, so once large mole-
cules have entered the tumour environment, they are more likely
to be retained. This passive targeting of tumours by large
molecules is referred to as the ‘enhanced permeability and
retention’ (EPR) effect.[3]
Owing to the clinical success of platinum-based cancer
drugs,[4] macromolecular derivatives have been evaluated in
an attempt to target tumours more effectively to reduce the
severe toxic side effects and to overcome resistance associated
with platinum agents.[5] In recent years, ruthenium compounds
have been shown to exhibit promising anticancer activity,[6]
with two compounds being evaluated in clinical trials.[7]
Ruthenium complexes are believed to bind with large biomole-
cules[8] in the plasma and consequently could take advantage of
the EPR effect. However, larger multinuclear ruthenium com-
plexes could potentially use the EPR effect without having to
bind to biomolecules.
There has been increasing interest in the anticancer proper-
ties of arene ruthenium (organometallic) compounds,[9] and
very recently, we found that rectangular tetranuclear arene
ruthenium complex cations incorporating 2,5-dioxydo-1,4-
benzoquinato (C6H2O4) and dipyridyl linkers were cytotoxic
against human ovarian (A2780) cancer cells and showed a
pronounced size effect,[10] as was observed by others[11] for
polynuclear compounds. While the smaller rectangles
containing 4,40-bipyridine (bipy) bridges, [Ru4(p-cymene)4
(bipy)2(C6H2O4)2]
4þ and [Ru4(hexamethylbenzene)4(bipy)2
1
(C6H2O4)2]
4þ are only moderately cytotoxic (IC50¼ 66 and
27 mM respectively) (IC50 being the drug concentration
necessary for 50% inhibition of cell viability), the larger
rectangles containing 1,2-bis(4-pyridyl)ethene (bpe) bridges,
[Ru4(p-cymene)4(bpe)2(C6H2O4)2]
4þ (Chart 1) and [Ru4(hexa-
methylbenzene)4(bpe)2(C6H2O4)2]
4þ show good cytotoxicities
(IC50¼ 6 and 4mMrespectively).We also prepared hexanuclear
arene ruthenium complexes that form hexacationic cages using
2,5-dioxydo-1,4-benzoquinato bridges and tridentate 2,4,6-tris
(4-pyridyl)1,3,5-triazine (tpt) panels, which are active against
human ovarian (A2780) cancer cells (Chart 1). The empty
hexaruthenium cage already possesses an IC50 value of
23 mM; using the platinum-containing cage, the cytotoxicity
doubles (IC50¼ 12 mM), and using the palladium-containing
cage, the activity goes up by a factor of 20 (IC50¼ 1mM),
whereas free Pt(acac)2 and Pd(acac)2 (acac¼ acetylacetonato)
are completely inactive owing to their insolubility in water.[12]
Direct evidence of this ‘Trojan Horse’ strategy to selectively
deliver and release a hydrophobic-containing host to cancer
cells was obtained using a fluorescent molecule as a cargo.[13]
We have now extended this strategy and synthesized larger
metalla-assemblies incorporating tetrapyridyl-porphyrin
panels, 5,10,15,20-tetra(4-pyridyl)porphyrin (tpp-H2) and
5,10,15,20-tetra(4-pyridyl)porphyrin-M(II) (M¼Ni (tpp-Ni),
Zn (tpp-Zn)), connected by dinuclear arene ruthenium clips
[Ru2(p-cymene)2(C2O4)Cl2], [Ru2(p-cymene)2(C6H2O4)Cl2],
[Ru2(indane)2(C6H2O4)Cl2], and [Ru2(nonylbenzene)2
(C6H2O4)Cl2] (C2O4¼ oxalato; C6H2O4¼ 2,5-dioxydo-1,4-
benzoquinonato¼ dobq). We have also studied the formation
of unsymmetrical metalla-cubes constructed from mixtures of
different porphyrin panels during the synthesis of the cubes. All
these octacationic metalla-cubes have been characterized and
evaluated in vitro against human ovarian cancer cell lines.
Results and Discussion
Syntheses, Solubility, and Stability
As shown previously, the synthesis of arene ruthenium
metalla-cubes [1],[14] [3],[15] [4],[16] and [6][15] is straight-
forward. Accordingly, for the nickel porphyrin derivatives
[Ru8(p-cymene)8(tpp-Ni)2(C2O4)4]
8þ (2) and [Ru8(p-
cymene)8(tpp-Ni)2(C6H2O4)4]
8þ (5), the addition of silver tri-
flate to the dinuclear metalla-clips [Ru2(p-cymene)2(C2O4)Cl2]
and [Ru2(p-cymene)2(C6H2O4)Cl2], in the presence of
5,10,15,20-tetra(4-pyridyl)porphyrin-Ni(II) (tpp-Ni) leads in
good yield to the formation of 2 and 5. The p-cymene ruthenium
metalla-cubes 1–6 are presented in Fig. 1.
Following the same two-step strategy in which the new
dinuclear complexes [Ru2(indane)2(C6H2O4)Cl2] and [Ru2
(nonylbenzene)2(C6H2O4)Cl2] are used as metalla-clips, the
metalla-cubes [Ru8(indane)8(tpp-H2)2(C6H2O4)4]
8þ ([9]) and
[Ru8(nonylbenzene)8(tpp-H2)2(C6H2O4)4]
8þ ([10]) were pre-
pared (Scheme 1), isolated as their triflate salts and character-
ized by IR, NMR, electrospray ionization mass spectrometry
(ESI-MS) and by elemental analysis (see below and Experi-
mental). The metalla-cubes are quite soluble in dichloro-
methane, acetonitrile, acetone, and DMSO but poorly soluble
in methanol and water. The stability of themetalla-cubes in D2O
was monitored by 1H NMR spectroscopy, and following 48 h of
heating at 608C, no degradation was observed.
Characterization
The 1H NMR spectra (in CD3CN or CD2Cl2) of 2, 5, 9, and 10,
the new metalla-cubes described herein, display a similar
signal pattern to the corresponding porphyrin (tpp-H2 or tpp-Ni)
and arene protons. In the case of metalla-cubes 2 and 5 (arene¼
p-cymene), four doublets are observed in the region
6.2–5.9 ppm for the arene protons, whereas in 9 (arene¼
indane), two doublets and two triplets and in 10 (arene¼
nonylbenzene), one doublet of doublets, two doublets and one
triplet are observed in the same region. In 9 and 10, an additional
signal at d,6.96 ppmcorresponding to theN–Hprotons of the
tpp-H2 porphyrin panels is observed, whereas in 5, 9, and 10,
the benzoquinonato singlet is observed at,6.2 ppm. Moreover,
the tpp panels give between 9.5 and 7.0 ppm a total of six
multiplets corresponding to four pyridyl and two pyrrole pro-
tons. The non-equivalence of the endo (pointing inwards) and
exo (pointing outwards) pyridyl protons is not surprising; a
similar signal pattern has been observed with the known
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metalla-cubes 1, 3, 4, and 6,[15] and is consistent with previous
observations in related metalla-prisms,[17] with the presence of
diastereotopic protons being attributed to a tilt of the dinuclear
metalla-clips and a twist of the two porphyrins panels, thus
leading to helical chirality (Fig. 2).
The IR spectra of 2, 5, 9, and 10, as well as the already
reported metalla-cubes 1, 3, 4, and 6, are dominated by absorp-
tions of the coordinated porphyrin panels with, in particular, a
strong in-plane N–H deformation at,1220 cm1 observed in 1,
4, 9, and 10,[18] and the bands assigned to the C¼C and C¼N
skeletal modes of the porphyrins located between 1620 and
1400 cm1.[19] Moreover, the bands associated with the
OO\OO bridges, including the strong C¼O stretching vibration
(at ,1530 cm1), are only slightly shifted compared with the
corresponding vibrations observed in the dinuclear complexes
[Ru2(p-cymene)2(C2O4)Cl2]
[20] and [Ru2(arene)2(C6H2O4)
Cl2].
[12] In addition to the porphyrin and OO\OO absorptions,
strong stretching vibrations due to the triflate anions (1260(s),
1030(s), 638(m) cm1) are also observed in the IR spectra of the
salts [1–6][CF3SO3]8 and [9–10][CF3SO3]8.
Under the conditions of ESI-MS, all the metalla-cubes 1–6,
9, and 10 are remarkably stable. The ESI-MS spectra of 2, 5, 9,
and 10 show peaks corresponding to [2þ (CF3SO3)4]4þ, [5þ
(CF3SO3)4]
4þ, [9þ (CF3SO3)4]4þ, and [10þ (CF3SO3)4]4þ, at
m/z 1045.0, 1095.5, 1035.5, and 1207.8 respectively, which are
assigned unambiguously on the basis of their characteristic
Ru8 isotope patterns. Fig. 3 shows the ESI-MS spectrum of
[9][CF3SO3]8 in acetonitrile.
Electronic absorption spectra of 2, 5, 9, and 10 as well as the
porphyrin panels (tpp-H2 and tpp-Ni) were acquired in dichloro-
methane at 105M concentration in the range 250–800 nm
(Fig. 4). The UV-visible spectra of all compounds are character-
ized by intense absorptions due to the porphyrin panels, includ-
ing the Soret band at,400 nm and a series of Q bands between
500 and 700 nm. In all complexes, compared with the free
porphyrins, the Soret band is blue-shifted and the full width at
half-maximum (Dn) increased. In the case of metalla-cube 9, the
full width at half-maximum (Dn¼ 1471 cm1) is 33% larger
than the width of tpp-H2 (1106 cm
1). In all metalla-cubes, a
weak hypsochromic shift of the Soret band and a strong
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Scheme 1. Synthesis of metalla-cubes 9 and 10 from metalla-clips 7 and 8.
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bathochromic shift of the Q bands are observed with respect
to the free porphyrins. These photophysical changes in the
UV-visible spectra of the metalla-cubes are characteristic of
sandwich-type porphyrin dimers.[21]
Unsymmetrical Metalla-Cubes
As mentioned above, metalla-cubes 1–6, 9, and 10 are particu-
larly stable under the conditions of ESI-MS. For this reason, we
used this technique to investigate the formation of unsymme-
trical metalla-cubes, i.e. the formation of metalla-cubes built
from two different porphyrin panels. Consequently, a stock
solution of the dinuclear metalla-clip [Ru2(p-cymene)2(C6H2O4)
Cl2] with silver triflate was freshly prepared in methanol. Next,
mixtures containing equimolar amount of porphyrin panels
(Mx1: tpp-H2þ tpp-Ni; Mx2: tpp-H2þ tpp-Zn; Mx3: tpp-Niþ
tpp-Zn; Mx4: tpp-H2þ tpp-Niþ tpp-Zn) were added to four
fractions of the stock solution and heated at reflux for 48 h,
leading to the formation of mixtures of symmetrical and
unsymmetrical metalla-cubes (in Mx1: 4þ 5þ 11; Mx2:
4þ 6þ 12; Mx3: 5þ 6þ 13; Mx4: 4þ 5þ 6þ 11þ 12þ 13) as
determined by 1HNMR spectroscopy. The precipitates obtained
were directly analysed by ESI-MS without further purification
or separation. All attempts to separate the metalla-cubes were
unsuccessful. The proposed structures of the unsymmetrical
metalla-cubes 11, 12, and 13 are presented in Fig. 5.
The ESI-MS spectrum of a solution of Mx1 shows the for-
mation of the expected metalla-cubes 4 and 5 as well as the
formation of the unsymmetrical metalla-cube [Ru8(p-cymene)8
(tpp-H2)(tpp-Ni)(C6H2O4)4]
8þ (11). In the same way, the for-
mation of [Ru8(p-cymene)8(tpp-H2)(tpp-Zn)(C6H2O4)4]
8þ (12)
and [Ru8(p-cymene)8(tpp-Ni)(tpp-Zn)(C6H2O4)4]
8þ (13) is
observed in mixtures Mx2 and Mx3 respectively. Finally, in
Mx4, the formation of all unsymmetrical and symmetrical
metalla-cubes can be observed by ESI-MS (Fig. 6). This study
confirms that the formation of metalla-cubes with two different
porphyrin panels is possible.
Antiproliferative Activity
The antiproliferative activity of the isolated metalla-cubes 1–6,
9, 10, the stoichiometricmixtures ofmetalla-cubes 4–6 (Table 1,
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entries 13 to 16) and the mixtures Mx1–Mx4 containing the
unsymmetrical metalla-cubes (Table 1, entries 9 to 12) were
evaluated against the A2780 (cisplatin-sensitive) and
A2780cisR (cisplatin-resistant) human ovarian cancer cell lines.
Their cytotoxicities, in comparison with cisplatin, are presented
in Table 1.
All compounds show similar cytotoxicities towards both
cisplatin-sensitive and cisplatin-resistant cancer cell lines, sug-
gesting that they do not share the same mechanisms of action
as the reference drug, i.e. cisplatin. Moreover, among the com-
pounds tested, additional trends can be drawn from these results:
the oxalato-containing metalla-cubes 1–3 are at least an order of
magnitude less cytotoxic than the 2,5-dioxydo-1,4-benzoquino-
nato analogues 4–6, indicating that the nature of the OO\OO
connecting spacer plays a crucial role. Similarly, the nature of
the arene ligand can influence the cytotoxicity of the metalla-
cubes. Indeed, the indane and nonylbenzene derivatives, 9 and
10 respectively, are significantly less cytotoxic than the corre-
sponding p-cymene analogue 4. In contrast, metallation of the
porphyrin core with the Zn2þ ion (metalla-cube 6) does not
modify the activity whereas metallation with Ni2þ (metalla-
cube 5) slightly reduces the cytotoxicity of the compound.
Interestingly, the mixtures Mx1–Mx4 containing the unsym-
metrical metalla-cubes (Table 1, entries 9 to 12) are the most
cytotoxic, with activities comparable with cisplatin or superior
to cisplatin in the resistant cancer cell line A2780cisR. This
distinctive activity is most probably due to the presence of the
unsymmetrical metalla-cubes 11, 12, and 13 but not due to
an additive effect of the metalla-cubes, as the stoichiometric
mixtures of the symmetrical metalla-cubes (entries 13 to 16)
clearly show, as expected, a cytotoxicity averaging the activity
of the parent complexes 4–6 (entries 4 to 6). The reason for such
a different activity of the unsymmetrical metalla-cubes com-
pared with their symmetrical counterparts is not clear at the
moment, but it could be linked to a better internalization of the
products, to a different mode of interaction in the cell, or to a
greater or lesser overall stability in the cellular environment.
Nevertheless, these results are quite unexpected and further
studies will be needed to provide an explanation for this
difference in cytotoxicity between symmetrical and unsymme-
trical metalla-cubes.
Conclusions
A series of octacationic metalla-cubes incorporating porphyrin
and metallo-porphyrin panels connected by oxalato and
2,5-dihydroxy-1,4-benzoquinonato arene ruthenium clips have
been prepared and characterized by spectroscopic methods.
These water-soluble metalla-cubes were screened for in vitro
anticancer activity against the A2780 and A2780cisR ovarian
cancer cell lines, and the larger assemblies were found to be
highly active and equally potent on both cell lines. It is likely that
these large complexes would be taken up more efficiently by
tumours owing to the EPR effect of cancer cells, thus providing a
degree of selectivity and ultimately giving a better efficacy.
Further studies are in progress to investigate the surprisingly low
IC50 values observed for the unsymmetrical metalla-cubes.
Experimental
General
1H and 13C{1H} spectra were recorded on a Bruker AvanceII
400 spectrometer using the residual protonated solvent as
internal standard ([D]chloroform: dH¼ 7.26 ppm, [D2]dichloro-
methane: dH¼ 5.32 ppm, and [D3]acetonitrile: dH¼ 1.94 ppm).
Infrared spectra were recorded as KBr pellets on a Perkin–Elmer
Fourier-transform (FT)-IR 1720X spectrometer. UV-visible
absorption spectra were recorded on an Uvikon 930 spectro-
photometer using precision cells made of quartz (1 cm).
Microanalyzes were performed by the Laboratory of Pharma-
ceutical Chemistry, University of Geneva (Switzerland).
Electro-spray mass spectra were obtained in positive-ion mode
with a Bruker FTMS 4.7-T BioAPEX II mass spectrometer.
The dimers [Ru(p-cymene)Cl2]2
[22] and [Ru(indane)Cl2]2,
[23]
the dinuclear p-cymene ruthenium complexes [Ru2(p-cymene)2
Table 1. IC50
A values with standard deviations of complexes 1]6, 9, 10, Mx1]Mx4 and stoichiometric mixtures
of 4]6 in A2780 and A2780cisR cell lines
Entry Compounds IC50 A2780 [mM] IC50 A2780cisR [mM]
1 1 57.6 1.9 44.2 5.6
2 2 41.5 5.8 49.5 8.9
3 3 34.5 7.5 35.7 8.0
4 4 8.0 4.5 7.0 4.5
5 5 15.5 4.5 14.8 4.5
6 6 7.6 0.6 9.8 0.4
7 9 19.4 4.5 21.5 3.8
8 10 21.2 2.5 24.1 5.2
9 Mx1 (4þ 5þ 11) 3.3 1.1 2.2 0.9
10 Mx2 (4þ 6þ 12) 2.8 0.1 2.0 0.5
11 Mx3 (5þ 6þ 13) 5.4 1.3 4.3 0.3
12 Mx4 (4þ 5þ 6þ 11þ 12þ 13) 3.2 0.4 2.5 0.3
13 4þ 5 14 3.9 16.2 5.0
14 4þ 6 7.1 1.5 9.2 0.5
15 5þ 6 13.8 5.2 16.4 4.3
16 4þ 5þ 6 12.4 1.4 16.5 1.3
17 cisplatin 2.2 0.8 12.2 1.2
AIC50 is the drug concentration necessary for 50% inhibition of cell viability.
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(C2O4)Cl2],
[20] [Ru2(p-cymene)2(C6H2O4)Cl2]
[12] and the
metalla-cubes 1,[14] 3,[15] 4,[16] 6[15] were prepared according to
published methods. [Ru(nonylbenzene)Cl2]2 was prepared by a
Birch-type reduction[24] of the commercially available (Sigma–
Aldrich) nonylbenzene. Addition of RuCl3nH2O in ethanol to
the non-isolated 3-nonylcylohexa-1,4-diene using standard
reaction and purification conditions afforded the dimer.[25] dH
(400MHz, CDCl3, 298K) 5.66 (dd,
3J 5.9, 3J 5.6, 4H, Hphenyl),
5.56 (t, 2H, Hphenyl), 5.36 (d, 4H, Hphenyl), 2.52 (t,
3J 7.9, 4H,
CH2a), 1.53 (m, 4H, CH2b), 1.27 (m, 24H, CH2), 0.86 (t,
3J 6.6,
6H, CH3).
13C{1H} NMR (100MHz, CDCl3, 298K) 102.8
(Cphenyl), 80.4 (CHphenyl), 79.9 (CHphenyl), 78.4 (CHphenyl), 33.8
(CH2a), 32.6 (CH2b), 30.2 (CH2), 30.1 (CH2), 30.0 (CH2), 30.0
(CH2), 23.4 (CH2), 14.4 (CH3). The porphyrin derivatives were
commercially available (Sigma–Aldrich, TriPorTech GmbH or
Frontier Scientific) and used as received. The other reagents
were purchased from Sigma–Aldrich and used as received.
Syntheses
Metalla-Clips 7 and 8
Amixture of [(arene)RuCl2]2 (7: indane, 500mg, 0.86mmol;
8: nonylbenzene, 647mg, 0.86mmol) and 2,5-dihydroxy-1,4-
benzoquinone (120mg, 0.86mmol) in ethanol (100mL) was
stirred at reflux for 24 h, then filtered. The black precipitate was
washed with cold ethanol, pentane, and dried under vacuum.
7: Yield: 528mg (95%). nmax/cm
1 3070 (w, aromatic,
C–H), 1629 (s, dobq, C¼O). lmax/nm (e/M1 cm1)
(1.0 105M,CH2Cl2) 268 (2.83 104). dH (400MHz, CDCl3,
298K) 6.31 (d, 3J 7.4, 8H, Hindane), 6.22 (d,
3J 7.3, 8H, Hindane),
6.15 (s, 8H, Hq), 6.12 (t, 8H, Hindane), 6.05 (t, 8H, Hindane),
3.06 (m, 16H, CH2indane), 2.95 (m, 8H, CH2indane).
13C{1H}
NMR (100MHz, CDCl3, 298K) 184.0 (CO), 104.2 (Cindane),
103.7 (Cindane), 102.0 (CHq), 83.0 (CHindane), 82.7 (CHindane),
82.5 (CHindane), 82.4 (CHindane), 30.3 (CH2indane), 23.4 (CH2in-
dane). Calc. for C24H22Cl2O4Ru2 (647.5): C 44.52, H 3.42. Found:
C 44.46, H 3.32%.
8: Yield: 690mg (98%). nmax/cm
1 3068 (w, aromatic,
C–H), 1630 (s, dobq, C¼O). lmax/nm (e/M1 cm1)
(1.0 105M,CH2Cl2) 275 (2.81 104). dH (400MHz, CDCl3,
298K) 5.65 (dd, 3J 5.9, 3J 5.6, 4H, Hphenyl), 5.56 (t, 2H, Hphenyl),
5.37 (d, 4H, Hphenyl), 2.51 (t,
3J 7.9, 4H, CH2a), 1.53 (m, 4H,
CH2b), 1.27 (m, 24H, CH2), 0.85 (t,
3J 6.6, 6H, CH3).
13C{1H}
NMR (100MHz, CDCl3, 298K) 184.2 (CO), 102.5 (Cphenyl),
80.5 (CHphenyl), 79.9 (CHphenyl), 78.4 (CHphenyl), 33.8 (CH2a),
32.8 (CH2b), 30.2 (CH2), 30.1 (CH2), 30.0 (CH2), 29.9 (CH2),
23.4 (CH2), 14.5 (CH3). Calc. for C36H50Cl2O4Ru2 (819.8):
C 52.74, H 6.15. Found: C 52.66, H 5.97%.
Metalla-Cubes [2][CF3SO3]8, [5][CF3SO3]8,
[9][CF3SO3]8, and [10][CF3SO3]8
A mixture of Ag(CF3SO3) (165mg, 0.64mmol) and [Ru2
(arene)2(OO\OO)2Cl2] (0.32mmol; 2: p-cymene, oxalato,
201mg; 5: p-cymene, dobq, 218mg; 9: indane, dobq, 207mg;
10: nonylbenzene, dobq, 262mg) in methanol (30mL) was
stirred at room temperature for 3 h, then filtered. To the red
filtrate, the corresponding porphyrin (0.16mmol; 2 and 5:
tpp-Ni, 108mg; 9 and 10: tpp-H2, 99mg) was added. The
solution was refluxed for 48 h, and the solvent removed under
vacuum. The residue was dissolved in dichloromethane (2, 5,
10) or acetonitrile (9) (3mL), and diethyl ether added to
precipitate the purple (2 and 5) or black (9 and 10) solid.
[2][CF3SO3]8: Yield: 305mg (79%). nmax/cm
1 3069 (m,
aromatic, C–H), 1521 (s, oxalato, C¼O), 1258 (s, triflate,
C–F). lmax/nm (e/M
1 cm1) (1.0 105M, CH2Cl2) 416
(4.09 105), 542 (0.47 105). dH (400MHz, CD2Cl2, 298K)
9.25 (d, 3J 6.3, 8H, Hpyr), 9.18 (d,
3J 7.1, 8H, H0a), 8.92 (d,
3J 7.3,
8H,Hb), 8.17 (d, 8H,Ha), 8.10 (d, 8H,H
0
pyr), 7.91 (d, 8H,H
0
b), 6.15
(m, 16H,Hp-cym), 5.97 (m,16H,Hp-cym), 3.05 (sept,
3J6.8, 4H,CH
(CH3)2), 2.45 (s, 12H, CH3), 1.49 (d, 24H, CH(CH3)2).
13C{1H}
NMR(100MHz,CD3CN, 298K) 172.3 (CO), 153.7 (CH
0
a), 151.2
(CHa), 149.4 (Cpyridyl), 140.1 (Cpyr), 139.9 (Cpyr), 133.5 (CH
0
b),
133.1 (CHb), 130.0 (CH
0
pyr), 129.6 (CH
0
pyr), 104.2 (Cp-cym), 101.3
(Cp-cym), 84.2 (CHp-cym), 83.8 (CHp-cym), 83.0 (CHp-cym), 82.6
(CHp-cym), 32.0 (CH(CH3)2), 21.8 (CH(CH3)2), 21.2 (CH(CH3)2),
17.5 (CH3). m/z (ESI) 1045.0 [2þ (CF3SO3)4]4þ. Calc. for
C176H160F24N16Ni2O40Ru8S8 (4777.7): C 44.24, H 3.37, N 4.69.
Found: C 44.01, H 3.29, N 4.34%.
[5][CF3SO3]8: Yield: 311mg (78%). nmax/cm
1 3068 (m,
aromatic, C–H), 1520 (s, dobq, C¼O), 1258 (s, triflate, C–F).
lmax/nm (e/M
1 cm1) (1.0 105M, CH2Cl2) 409
(3.45 105), 533 (0.58 105). dH (400MHz, CD3CN, 298K)
8.80 (d, 3J 6.5, 8H, Hpyr), 8.77 (d,
3J 7.2, 8H, H0a), 8.44 (d,
3J 7.1,
8H, Hb), 8.32 (d, 8H, Ha), 8.14 (d, 8H, H
0
pyr), 7.39 (d, 8H, H
0
b),
6.19 (d, 3J 5.7, 8H, Hp-cym), 6.15 (d,
3J 5.6, 8H, Hp-cym), 6.11 (s,
8H, Hq), 6.01 (d, 8H, Hp-cym), 5.98 (d, 8H, Hp-cym), 3.10 (sept,
3J
6.6, 8H, CH(CH3)2), 2.42 (s, 24H, CH3), 1.52 (m, 48H, CH
(CH3)2).
13C{1H}NMR (100MHz, CD3CN, 298K) 184.1 (CO),
183.6 (CO), 152.5 (CH0a), 150.6 (CHa), 150.5 (Cpyridyl), 141.1
(Cpyr), 140.8 (Cpyr), 132.5 (CH
0
b), 132.0 (CHb), 131.2 (CH
0
pyr),
130.6 (CH0pyr), 104.0 (Cp-cym), 101.9 (Cp-cym), 98.6 (CHq), 83.8
(CHp-cym), 83.2 (CHp-cym), 82.5 (CHp-cym), 82.3 (CHp-cym), 31.4
(CH(CH3)2), 21.9 (CH(CH3)2), 21.4 (CH(CH3)2), 17.5 (CH3).
m/z (ESI) 1095.5 [5þ (CF3SO3)4]4þ, 1510.3 [5þ (CF3SO3)5]3þ.
Calc. for C192H168F24N16Ni2O40Ru8S8 (4977.9): C 46.33, H 3.40,
N 4.50. Found: C 46.08, H 3.28, N 4.41%.
[9][CF3SO3]8: Yield: 315mg (83%). nmax/cm
1 3070 (m,
aromatic, C–H), 1528 (s, dobq, C¼O), 1260 (s, triflate, C–F),
1217 (s, porphyrin, N–H). lmax/nm (e/M
1 cm1)
(1.0 105M, CH2Cl2) 413 (3.49 105), 519 (0.54 105). dH
(400MHz, CD3CN, 298K) 8.99 (m, 8H, Hpyr), 8.90 (d,
3J 7.2,
8H, H0a), 8.82 (m, 16H, HbþHa), 8.29 (m, 8H, H0pyr), 7.43 (d, 3J
7.4, 8H, H0b), 6.33 (d,
3J 6.3, 8H, Hindane), 6.25 (d,
3J 6.2, 8H,
Hindane), 6.15 (s, 8H, Hq), 6.08 (t, 8H, Hindane), 6.02 (t, 8H,
Hindane), 3.06 (m, 16H, CH2indane), 2.95 (m, 8H, CH2indane),
6.96 (s, 4H, NH). 13C{1H} NMR (100MHz, CD3CN, 298K)
184.9 (CO), 184.8 (CO), 153.5 (CH0a), 152.2 (CHa), 151.7
(Cpyridyl), 133.7 (Cpyr), 133.5 (Cpyr), 132.5 (CH
0
b), 132.0
(CHb), 127.0 (CH
0
pyr), 126.9 (CH
0
pyr), 105.1 (Cindane), 104.8
(Cindane), 102.9 (CHq), 83.2 (CHindane), 83.0 (CHindane), 82.8
(CHindane), 82.7 (CHindane), 30.7 (CH2indane), 23.5 (CH2indane).
m/z (ESI) 1035.5 [9þ (CF3SO3)4]4þ. Calc. for C184H140F24
N16O40Ru8S8 (4736.2): C 46.66, H 2.98, N 4.73. Found:
C 46.44, H 2.92, N 4.58%.
[10][CF3SO3]8: Yield: 337mg (78%). nmax/cm
1 3068 (m,
aromatic, C–H), 1522 (s, dobq, C¼O), 1259 (s, triflate, C–F),
1220 (s, porphyrin, N–H). lmax/nm (e/M
1 cm1)
(1.0 105M, CH2Cl2) 412 (4.05 105), 522 (0.69 105). dH
(400MHz, CD3CN, 298K) 8.90 (d,
3J 6.5, 8H, Hpyr), 8.84 (d,
3J
7.2, 8H,H0a), 8.63 (m, 16H,HbþHa), 8.30 (d, 8H,H0pyr), 7.42 (d,
3J 7.4, 8H, H0b), 6.33 (dd,
3J 5.6, 3J 6.0, 16H, Hphenyl), 6.25 (s,
8H, Hq), 6.15 (t,
3J 5.6, 8H, Hphenyl), 6.09 (dd,
3J 5.6, 3J 6.0, 8H,
Hphenyl), 6.02 (d,
3J 6.0, 8H, Hphenyl), 2.77 (t,
3J 7.8, 16H, CH2a),
1.52 (m, 16H, CH2b), 1.33 (m, 96H, CH2), 0.89 (m, 24H, CH3),
6.96 (s, 4H, NH). 13C{1H} NMR (100MHz, CD3CN, 298K)
7
185.2 (CO), 184.8 (CO), 153.5 (CH0a), 152.5 (CHa), 152.2
(Cpyridyl), 132.9 (Cpyr), 132.7 (Cpyr), 132.6 (CH
0
b), 129.3
(CHb), 129.2 (CH
0
pyr), 123.8 (CH
0
pyr), 108.5 (Cq), 102.8 (CHq),
90.1 (Cphenyl), 89.8 (Cphenyl), 80.4 (CHphenyl), 79.9 (CHphenyl),
78.4 (CHphenyl), 33.8 (CH2a), 32.6 (CH2b), 30.2 (CH2), 30.0
(CH2), 29.9 (CH2), 23.4 (CH2), 14.4 (CH3). m/z (ESI) 1207.8
[10þ (CF3SO3)4]4þ. Calc. for C232H252F24N16O40Ru8S8
(5425.6): C 51.36, H 4.68, N 4.13. Found: C 51.10, H 4.61,
N 4.02%.
Cell Culture and Inhibition of Cell Growth
Human A2780 and A2780cisR ovarian carcinoma cells were
obtained from the European Centre of Cell Cultures (ECACC,
Salisbury, UK) and maintained in culture as described by
the provider. The cells were routinely grown in RPMI 1640
medium with GlutaMAXTM containing 10% fetal calf serum
(FCS) and antibiotics (penicillin and ciproxin) at 378C and
5% CO2. For the evaluation of growth inhibition, the cells
were seeded in 96-well plates and grown for 24 h in complete
medium. Complexes were added to the required concentration
and added to the cell culture for 72 h incubation. Solutions of
the compounds were applied by diluting a freshly prepared
stock solution of the corresponding compound in aqueous
RPMI medium with GlutaMAX (20mM). The MTT (thiazolyl
blue tetrazolium bromide) test was performed in the last 2 h
of the experiment without changing the culture medium. Fol-
lowing drug exposure, MTT was added to the cells at a final
concentration of 0.25mgmL1 and incubated for 2 h, then the
culture medium was aspirated and the violet formazan (arti-
ficial chromogenic precipitate of the reduction of tetrazolium
salts by dehydrogenases and reductases) dissolved in DMSO.
The optical density of each well (96-well plates) was quanti-
fied three times in triplicates at 540 nm using a multiwell plate
reader (iEMS Reader MF, Labsystems, US), and the percen-
tage of surviving cells was calculated from the ratio of
absorbance of treated to untreated cells. The IC50 values for
the inhibition of cell growthwere determined by fitting the plot
of the logarithmic percentage of surviving cells against the
logarithm of the drug concentration using a linear regression
function. The median value and the median absolute deviation
were obtained from Excel software (Microsoft) and those
values are reported in Table 1.
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